<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":6763,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
In re Lupron Mktg. & Sales Practices Litigation (Rohn v. TAP Pharmaceutical Products, Inc.), 677 F.3d 21 (1st Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/63be6f0340dbaefae64eb65c545b08e3'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/63be6f0340dbaefae64eb65c545b08e3'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1HK2OS003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HK2OS003">Previous Result: <span>United States ex rel. Westlund v. Lab. C...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1HK2P6003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HK2P6003">Next Result: <span>Hooper v. UNUM Life Ins. Co. of America,...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='In re Lupron Mktg. &amp; Sales Practices Litigation (Rohn v. TAP Pharmaceutical Products, Inc.), 677 F.3d 21 (1st Cir. 2012), Court Opinion'>
In re Lupron Mktg. &amp; Sales Practices Litigation (Rohn v. TAP Pharmaceutical Products,...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>In re Lupron Mktg. & Sales Practices Litigation (Rohn v. TAP Pharmaceutical Products, Inc.), 677 F.3d 21 (1st Cir. 2012), Court Opinion</div>
<div class='docId'>X1HK07U003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>In re Lupron Mktg. & Sales Practices Litigation (Rohn v. TAP Pharmaceutical Products, Inc.)</div>
<div class='displayCitation'>2012 BL 100841</div>
<div class='displayCitation'>2012 BL 100972</div>
<div class='displayCitation'>677 F.3d 21</div>
<div class='displayCitation'>bna a0d1q8r5a5</div>
<div class='displayCitation'>wkf1case:26017919</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HK07U003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="In re Lupron Mktg. &amp; Sales Practices Litigation (Rohn v. TAP Pharmaceutical Products, Inc.), 677 F.3d 21 (1st Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="In re Lupron Mktg. &amp; Sales Practices Litigation (Rohn v. TAP Pharmaceutical Products, Inc.)" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1HK07U003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HK07U003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HK07U003" /><input id="title" name="title" type="hidden" value="In re Lupron Mktg. &amp; Sales Practices Litigation (Rohn v. TAP Pharmaceutical Products, Inc.), 677 F.3d 21 (1st Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="63be6f0340dbaefae64eb65c545b08e3" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HK07U003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%36%33be%36f%30%33%34%30dbaefae%36%34eb%36%35c%35%34%35b%30%38e%33%2Fdocument%2FX%31HK%30%37U%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/bcite/X1HK07U003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/bcite/X1HK07U003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/bcite/X1HK07U003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/related_content/X1HK07U003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1705110339587";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">677 F.3d 21</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 10-2494, 11-1329.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 100972</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, First Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
In re LUPRON MARKETING AND SALES PRACTICES LITIGATION. Audrey Rohn,
individually and as executrix of the estate of Dennis Rohn; Barbara Sensing;
Valerie Samsell, Plaintiffs, Appellants, Milton Greene; Crossroads
Acquisition Corp.; William M. Porter; Liberty National Life Insurance
Company; United American Insurance Company; Cobalt Corporation; AETNA, Inc.,
Plaintiffs, William M. Porter, Plaintiff, Appellee, v. TAP Pharmaceutical
Products, Inc.; Abbott Laboratories; Takeda Pharmaceutical Company, Limited,
Defendants, Dana Farber/Harvard Cancer Center, Interested Party, Appellee.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 10-2494, 11-1329.
</center></p>
<p><center>
Heard February 8, 2012. Decided April 24, 2012.
</center></p>
<span CLASS="page_no" data-cite="677 f 3d 22" data-cite-type="PrimaryFederalReporter" data-cite-pageno="22" data-primary-citation="677 F.3d 21">[*22]</span> <div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the District of
Massachusetts, Richard G. Stearns, J.
<span CLASS="page_no" data-cite="677 f 3d 23" data-cite-type="PrimaryFederalReporter" data-cite-pageno="23" data-primary-citation="677 F.3d 21">[*23]</span> 
</p></div>
<div id="para2" printdualcolumn="true"><p>
Donald E. Haviland, Jr., with whom Michael J. Lorusso and Haviland Hughes,
LLC were on brief, for appellants.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Thomas M. Sobol, with whom Edward Notargiacomo, Hagens Berman Sobol Shaprio
LLP, Jeffrey L. Kodroff, John A. Macoretta, Specter Roseman &amp; Kodroff, P.C.,
David S. Stellings, Daniel R. Leathers, Lieff Cabraser Heimann &amp; Bernstein,
LLP, Lisa M. Mezzetti, and Cohen Milstein Sellers &amp; Toll PLLC were on brief,
for appellee William M. Porter.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Martin M. Fantozzi, with whom Mariana Korsunsky and Goulston &amp; Storrs, P.C.
were on brief, for appellee Dana Farber/Harvard Cancer Center.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before LYNCH, Chief Judge, SOUTER, Associate Justice,<a HREF="#fn*00" name="fnref_fn*00">[fn*]</a> and LIPEZ,
Circuit Judge.
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span class="fr"><a HREF="#fnref_fn*00" name="fn*00">[fn*]</a></span> The Hon. David H. Souter, Associate Justice (Ret.) of the Supreme
Court of the United States, sitting by designation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
LYNCH, Chief Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants, a small dissident group ("the Samsell plaintiffs"), are within
a larger class of medical patient consumers in a case alleging fraud in
overcharging for the medication Lupron. These plaintiffs, along with
insurers and private
<span CLASS="page_no" data-cite="677 f 3d 24" data-cite-type="PrimaryFederalReporter" data-cite-pageno="24" data-primary-citation="677 F.3d 21">[*24]</span> 
health care providers, have achieved a major settlement agreement which was
approved by the district court. The total amount of the settlement was $150
million, of which $40 million was allocated to consumers. That agreement
provided that if there were unclaimed monies from the $40 million consumer
settlement pool even after full recovery to consumer plaintiffs, all
unclaimed funds would go into a cy pres fund to be distributed at the
discretion of the trial judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Samsell plaintiffs appeal from the district court's distribution of
the $11.4 million cy pres fund to the Dana Farber/Harvard Cancer Center and
the Prostate Cancer Foundation ("DF/HCC") for work on the treatment of the
diseases for which Lupron is prescribed. The Samsell plaintiffs make a
series of subordinate attacks, all designed to increase the sums paid to
them, though they have already recovered more than 100% of their actual
damages. The award is defended by the plaintiff class and, naturally, by the
recipient DF/HCC. The defendant manufacturer of Lupron, having settled the
case, has not filed a brief with us.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We address for the first time the procedural and substantive standards for
distribution of cy pres funds; in doing so, we express our unease with
federal judges being put in the role of distributing cy pres funds at their
discretion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finding no <span CLASS="page_no" data-cite="2012 bl 100972 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> error, we affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In 2001, the Department of Justice initiated criminal proceedings against
TAP Pharmaceutical Products, Inc., ("TAP")<a HREF="#fn100" name="fnref_fn100">[fn1]</a> for violation of the
Prescription Drug Marketing Act of 1987, Pub. L. No. <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/1?citation=USACTS%20100-293&amp;summary=yes#jcite">100-293</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/1?citation=102%20stat%2095&amp;summary=yes#jcite">102 Stat. 95</a>.
TAP admitted that from 1991 to 2001 it had encouraged doctors to improperly
bill Medicare for free samples of its cancer drug Lupron so that they would
continue to prescribe Lupron instead of less expensive, similarly effective
drugs. Lupron is prescribed for prostate cancer in men, endometriosis and
infertility in women, central precocious puberty in children, and
preoperative treatment of patients with anemia caused by uterine fibroids.
TAP encouraged physicians to bill Medicare for Lupron at an inflated Average
Wholesale Price ("AWP") that TAP provided to an industry publication used by
Medicare and insurance plans to establish reimbursement schedules for
prescription drugs including Lupron. TAP pled guilty and paid a criminal
fine of $290 million as well as civil restitution of nearly $600 million to
Medicare and Medicaid and $25.5 million to the fifty states and the District
of Columbia.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On the heels of TAP's guilty plea, three groups &mdash; individual consumer
purchasers of Lupron, private health care plans, and insurers &mdash; brought nine
putative class action lawsuits against TAP to recover over-payment incurred
as a result of TAP's practices. <i>See In re: Lupron Mktg. &amp; Sales Practices</i>
<i>Litig.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XADQV9?jcsearch=245%20f%20supp%202d%20280&amp;summary=yes#jcite">245 F.Supp.2d 280</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XADQV9?jcsearch=245%20f%20supp%202d%20280&amp;summary=yes#jcite">285</a> (D.Mass.2003). Private insurers and health
care plans had used the inflated AWP, as had Medicare and Medicaid, to
determine their reimbursement payments to doctors for Lupron. The inflated
AWP also resulted in higher out-of-pocket payments for patients on any
portions of Lupron payments that were not covered by their insurance.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Multi-District Litigation Panel consolidated all nine actions in the
District of Massachusetts for pretrial proceedings.
<span CLASS="page_no" data-cite="677 f 3d 25" data-cite-type="PrimaryFederalReporter" data-cite-pageno="25" data-primary-citation="677 F.3d 21">[*25]</span> 
<i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XADQV9?jcsearch=245%20F.%20Supp.%202d%20280&amp;summary=yes#jcite">Id</a>.</i>The consolidated class action was brought under the civil provisions of
the Racketeer Influenced and Corrupt Organizations Act ("RICO"),
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XEHSS6003?jcsearch=18%20usc%201962&amp;summary=yes#jcite">18 U.S.C. &sect; 1962</a>, as well as under state consumer protection statutes and
theories of common-law fraud and unjust enrichment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court dismissed the conspiracy claims involving physicians
under RICO because the complaint neither named a single doctor as a
defendant nor alleged that the doctors who benefitted from the discounted
purchases or free samples of Lupron were even aware of one another's
existence as participants in a purported scheme to defraud. That dismissal
is important for reasons stated later. The district court allowed the
remaining conspiracy claims under RICO to proceed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 11, 2004, the MDL parties informed the district court that they
had reached a settlement as to all groups of plaintiffs and moved for
preliminary approval of the negotiated agreement. On November 4, 2004,
appellant Valerie Samsell, a consumer, filed a motion to intervene. The
district court allowed Samsell to intervene "for the purpose of
participating in the process established by the court for the evaluation of
the proposed settlement." <span CLASS="page_no" data-cite="2012 bl 100972 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> <i>In re: Lupron Mktg. &amp; Sales Practices Litig.</i>, No.
<cite>01-CV-10861</cite> (D.Mass. Nov. 17, 2004). On November 24, 2004, the district
court issued an order preliminarily approving the proposed settlement and
settlement class. <i>In re: Lupron Mktg. &amp; Sales Practices Litig.</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XGALHH?jcsearch=345%20f%20supp%202d%20135&amp;summary=yes#jcite">345 F.Supp.2d 135</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XGALHH?jcsearch=345%20f%20supp%202d%20135&amp;summary=yes#jcite">138-39</a> (D.Mass.2004).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In April 2005, the district court held a three-day fairness hearing on the
proposed settlement. <i>See In re Lupron Mktg. &amp; Sales Practices Litig.</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20federal%20rules%20decisions%2075&amp;summary=yes#jcite">228 F.R.D. 75</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20federal%20rules%20decisions%2075&amp;summary=yes#jcite">78</a> (D.Mass.2005). Samsell called witnesses to testify,
submitted seven depositions of additional witnesses, and presented
twenty-three exhibits. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20F.R.D.%2075&amp;summary=yes#jcite">Id.at 83-84</a>. In addition, Samsell filed several
objections to the settlement, including an objection that the amount of the
settlement allocated to the class of consumer purchasers of Lupron was
inadequate. On May 12, 2005, having found that the settlement was fair,
reasonable and adequate, the district court issued a memorandum and order
approving the settlement and certifying the class. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20F.R.D.%2075&amp;summary=yes#jcite">Id.at 78, 98</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The approved settlement agreement allocated $40 million of the $150
million total settlement to consumer purchasers of Lupron. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20F.R.D.%2075&amp;summary=yes#jcite">Id.at 86</a>. It
allowed these consumers to recover 30% of their total out-of-pocket payments
for Lupron, or $100, whichever sum was greater. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20F.R.D.%2075&amp;summary=yes#jcite">Id.at 87</a>. Although the
district court could not determine the size of the consumer class with
certainty, given the high mortality rate associated with prostate cancer and
the extended class period of more than twenty years, the district court
found that the class likely included tens if not hundreds of thousands of
consumer purchasers of Lupron or their estates. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20F.R.D.%2075&amp;summary=yes#jcite">Id.at 88.</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court's decision to approve the settlement agreement rested
in part on an analysis of the likely damages suffered by the class
plaintiffs, as presented by expert witnesses. Plaintiffs' two experts, Dr.
Hartman and Dr. Rosenthal, testified that the allocation of the settlement
funds was deliberately weighted to favor the consumer members of the class.
<i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20F.R.D.%2075&amp;summary=yes#jcite">Id.at 87</a> &amp; n. 26. Consumers were allocated approximately 27% of the total
settlement, even though the consumer claims most likely accounted for 9% to
13% of the total over-charges. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20F.R.D.%2075&amp;summary=yes#jcite">Id.at 87</a> n. 26. The experts also testified
that approximately 30% of the consumers' out-of-pocket expenses for Lupron
represented a reasonable estimate of the actual overcharge that consumers
suffered as a result of the inflated AWP. <i></i><span CLASS="page_no" data-cite="677 f 3d 26" data-cite-type="PrimaryFederalReporter" data-cite-pageno="26" data-primary-citation="677 F.3d 21">[*26]</span> <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XOKUTBQNB5G0?jcsearch=228%20F.R.D.%2075&amp;summary=yes#jcite">Id.

at 87</a> &amp; n. 26. The settlement agreement was designed to pay consumers 100%
of this estimated overcharge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Significantly, the settlement agreement expressly anticipated the
possibility of either a shortage or a surplus in the portion of the
settlement funds allocated to consumers. In the case of a shortage, the
settlement agreement provided that payments to consumers would be reduced on
a pro rata basis. In the case of a surplus, the agreement provided:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      All unclaimed funds remaining in the Net Consumer Settlement Pool
    shall be distributed in the discretion of the Settlement Court as it
    deems appropriate. If all or part of any unclaimed funds is
    distributed to one or more charitable organizations, TAP reserves
    whatever <span CLASS="page_no" data-cite="2012 bl 100972 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> right it may have to claim any appropriate tax deductions
    for any such charitable donation(s), and no member of the Consumer
    Class or the TPP [Third Party Payers] Class or the SHP [Settling
    Health Plans] Group shall have a claim to any such deductions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following the district court's approval of the settlement agreement, the
Samsell plaintiffs said they would pursue appeals of the settlement
agreement unless they received more. As a result, all of the parties,
including the Samsell plaintiffs, negotiated and executed an "implementation
agreement." The implementation agreement provided an increase in the
payments to the consumer class from 30% to 50% of their out-of-pocket
expenses for Lupron. This meant that consumers would receive 167% of the
damages the district court had found they had suffered. In return, the
Samsell plaintiffs and other objectors agreed to withdraw their pending
appeals and other objections to the settlement, to rescind their opt-out
requests, to participate in the claims process, and to waive their right to
appeal from the final judgment approving the settlement. The implementation
agreement also awarded incentive payments to certain objectors, including
Samsell, and permitted her attorneys to seek an award of their fees. On
August 26, 2005, the district court entered its final order approving the
settlement agreement as modified by the implementation agreement. <i>In re:</i>
<i>Lupron Mktg. &amp; Sales Practices Litig.</i>, No. <cite>01-CV-10861</cite> (D.Mass. Aug. 26,
2005).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties initiated a national notice campaign designed to expose 80% of
the members of the consumer class on three or more occasions to notice of
the proposed settlement and the procedure for submitting claims. Notice was
published in 947 newspapers, as well as through public service
announcements, Lupron-related websites, and media coverage of the
settlement. An interactive claims information website and a toll-free
telephone number to take questions from class members were established.
Consumer Notice Packets were mailed to the attorneys general of the fifty
states, Puerto Rico, and the Virgin Islands. Direct mail was not used
because of privacy and practicality concerns.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Consumers were allowed more than four years to file their claims. Despite
these efforts, only about 11,000 individuals &mdash; a fraction of the estimated
tens or hundreds of thousands of members of the consumer class &mdash; filed
claims, given the high mortality rate among members of the class. At the
conclusion of the claims administration process, approximately $11.4 million
remained unclaimed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The plaintiffs requested that the district court determine a plan for
distribution of the $11.4 million in unclaimed funds. On January 13, 2009,
during a hearing regarding the proposed disposition of the unclaimed funds,
the district court stated its intention to "ensure that any distribution,
<span CLASS="page_no" data-cite="677 f 3d 27" data-cite-type="PrimaryFederalReporter" data-cite-pageno="27" data-primary-citation="677 F.3d 21">[*27]</span> 
whatever is done, is done both with the highest benefit of the class,
present and absent in mind; that the money is distributed and spent
responsibly; and, that it serves the highest purpose that was <span CLASS="page_no" data-cite="2012 bl 100972 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> intended by
the litigation and the ultimate settlement." After hearing the plaintiffs'
alternative proposals, the district court narrowed its choice to three
options: (1) awarding the unclaimed funds as additional compensation to the
members of the consumer class who had already made claims and been paid in
full under the settlement agreement; (2) conducting a supplemental claims
process with a goal of identifying absent class members; and (3) making a cy
pres award of the unclaimed funds for research addressing the medical
conditions treated by Lupron for the benefit of the present and future
patients suffering from these afflictions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In response to a proposal to distribute some of the residual funds to a
program created by a group of four doctors affiliated with Brigham and
Women's Hospital ("the Loughlin Group"), the district judge disclosed that
for nearly twelve years he had served as an uncompensated trustee on the
board of Vincent Memorial Hospital, which is affiliated with the
Massachusetts General Hospital. The judge said he was considering whether
this posed any issues. The Samsell plaintiffs, who were present at the
hearing, did not, either then or later, raise any objection regarding the
judge's position on the board at Vincent or his continued involvement in the
proceedings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On May 19, 2009, the district court issued a memorandum and order stating
its intention to make a cy pres award and distribute the residual funds for
the purpose of funding research into the causes and treatments of
Lupron-related conditions. <i>In re: Lupron Mktg. &amp; Sales Practices Litig.</i>, No.
<cite>01-CV-10861</cite>, <cite>2009 WL 1395411</cite> (D.Mass. May 19, 2009). The district court
stated that it was inclined to distribute the funds to the Loughlin Group
and invited the Loughlin Group to submit a formal proposal for the court's
review. <i></i><cite>Id.at *2</cite>. The Samsell plaintiffs appealed this order to this court;
we concluded that we lacked jurisdiction to review a non-final order and
dismissed the appeal. <i>See Samsell v. TAP Pkarm. Prods.</i>, No. <cite>09-1887</cite> (1st
Cir. Jan. 7, 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Having learned about the residual funds from the May 19, 2009 order, a
different group, DF/HCC, petitioned the district court to consider its
proposal with respect to the unclaimed funds. The district court granted the
request. On May 25, 2010, the district court invited the public to comment
on the proposals advanced both by the Loughlin Group and by DF/HCC.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On August 6, 2010, the court issued a memorandum and order stating that it
had decided to make a cy pres award of all of the unclaimed settlement funds
to DF/HCC, to be made in three installments. <i>In re: Lupron Mktg. &amp; Sales</i>
<i>Practices Litig.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LCQ4HG82?jcsearch=729%20f%20supp%202d%20492&amp;summary=yes#jcite">729 F.Supp.2d 492</a> (D.Mass.2010). The court explained that
it had rejected the option of a supplemental claims process because it would
be "exorbitantly expensive (estimated at upwards of $1.74 million),
time-consuming, and would likely recruit few new claimants given the high
mortality rate among members of the class." <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LCQ4HG82?jcsearch=729%20F.%20Supp.%202d%20492&amp;summary=yes#jcite">Id.at 494</a> n. 4. No attack is
made on that finding in this appeal. The court further explained that its
decision to award the funds to DF/HCC was influenced by four principal
<span CLASS="page_no" data-cite="2012 bl 100972 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> considerations. First, DF/HCC is an established organization "with
experience in managing grant programs." <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LCQ4HG82?jcsearch=729%20F.%20Supp.%202d%20492&amp;summary=yes#jcite">Id.at 497</a>. Second, its proposal
"leverage[d] existing institutional infrastructure, funding mechanisms, and
. . . relationships," which would reduce startup and administrative costs.
<i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LCQ4HG82?jcsearch=729%20F.%20Supp.%202d%20492&amp;summary=yes#jcite">Id</a>.</i>Third,
<span CLASS="page_no" data-cite="677 f 3d 28" data-cite-type="PrimaryFederalReporter" data-cite-pageno="28" data-primary-citation="677 F.3d 21">[*28]</span> 
the proposal was designed to have "a broad national outreach to attract
large-scale research collaborations, innovative pilot projects, promising
young investigators, and talented graduate students." <i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LCQ4HG82?jcsearch=729%20F.%20Supp.%202d%20492&amp;summary=yes#jcite">Id</a>.</i>Finally, DF/HCC
"propose[d] to dedicate an appropriate portion of the funds to research
involving cures for . . . Lupron-treated diseases and conditions" other than
prostate cancer. <i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LCQ4HG82?jcsearch=729%20F.%20Supp.%202d%20492&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court also crafted an over-sight plan which required DF/HCC
to submit regular reports to account for the grant awards and expenditures.
<i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LCQ4HG82?jcsearch=729%20F.%20Supp.%202d%20492&amp;summary=yes#jcite">Id.at 497-98</a>. The award would be paid to DF/HCC in three installments as
explicitly authorized by the district court. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LCQ4HG82?jcsearch=729%20F.%20Supp.%202d%20492&amp;summary=yes#jcite">Id.at 498</a>. The first
installment was ordered disbursed to DF/HCC on November 16, 2010. The
Samsell plaintiffs have not sought a stay of the disbursements.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On December 16, 2010, Valerie Samsell and Audrey Rohn filed a Notice of
Appeal from the November 16, 2010 Order. On January 5, 2011, Samsell filed
an Amended Notice of Appeal to add Barbara Sensing as an appellant.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Procedural Objections</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellees attempt to short stop this appeal on several procedural grounds.
We dispose of these procedural objections quickly.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, appellee William Porter, who represents the certified consumer
class, argues that the appeals are untimely because they were not filed
within 30 days of the August 6, 2010 order, which he asserts was a final
decision. Appellee DF/HCC argues that appellants Rohn and Samsell timely
filed their appeals within 30 days of the November 16, 2010 order disbursing
initial payment to DF/HCC, which they consider the pertinent order. But they
say that appellant Sensings appeal is still untimely because it was not
filed within 30 days of any order.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The relevant "order" which starts our analysis is the August 6, 2010 order
awarding the cy pres distribution to DF/HCC. The later November 16, 2010
disbursement order was a mere ministerial order. <i>See, e.g., Am. Ironworks &amp;</i>
<i>Erectors Inc. v. N. Am. Constr. Corp.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X50OK3?jcsearch=248%20f%203d%20892&amp;summary=yes#jcite">248 F.3d 892</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X50OK3?jcsearch=248%20f%203d%20892&amp;summary=yes#jcite">898</a> (9th Cir.2001) ("A
mere ministerial order, such as . . . an order to disburse funds from the
court registry, is not a final appealable order.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Not all orders qualify as appealable orders. A notice of appeal in a civil
case "must be filed with the district clerk within 30 days after entry of
the judgment or order appealed from." <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X135J6G003?jcsearch=Fed%20R.App.%20P.%204(a)(1)(A)&amp;summary=yes#jcite">Fed: R.App. P. 4(a)(1)(A)</a>. A judgment
or order is "entered" for Rule 4(a) purposes "when the judgment or order is
entered in the civil docket . . . [and] set forth on a separate document, or
150 days have run from entry of the judgment or order in the civil docket."
Fed. R.App. P. <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X135J6G003?jcsearch=Fed.%20R.App.%20P.%204(a)(7)(A)(ii)&amp;summary=yes#jcite">4</a>(a)(7)(A)(ii). If an order is not set forth on a separate
document, it is not considered "entered" and is not itself appealable until
150 days after entry in the civil docket. <i>Colon-Santiago v. Rosario</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X145SMQ003?jcsearch=438%20f%203d%20101&amp;summary=yes#jcite">438 F.3d 101</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X145SMQ003?jcsearch=438%20f%203d%20101&amp;summary=yes#jcite">108</a> (1st Cir.2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, the August 6, 2010 order was not set forth on a separate document,
but set forth on pages <span CLASS="page_no" data-cite="2012 bl 100972 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> seven through nine of a nine-page memorandum
containing the court's reasoning. It fails the "separate document"
requirement. <i>See Nunez-Soto v. Alvamdo</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3P23E?jcsearch=956%20f%202d%201&amp;summary=yes#jcite">956 F.2d 1</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3P23E?jcsearch=956%20f%202d%201&amp;summary=yes#jcite">2</a> (1st Cir.1992)
(explaining that the Federal Rules of Civil Procedure require "that a
judgment be set forth on a separate document and not simply tacked on to a
memorandum or opinion").
<span CLASS="page_no" data-cite="677 f 3d 29" data-cite-type="PrimaryFederalReporter" data-cite-pageno="29" data-primary-citation="677 F.3d 21">[*29]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The order was not "entered" for purposes of appeal until January 3, 2011,
150 days after August 6, 2010. The 30-day period for appealing from that
order expired 30 days later, on February 2, 2011. Because all of the
appellants filed before February 2, 2011, their appeals are timely.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, appellees argue that the Samsell plaintiffs lack standing because
they are unnamed, nonparty class members who have never objected to the
settlement agreement under which they have accepted full payment for their
losses.<a HREF="#fn200" name="fnref_fn200">[fn2]</a> Only parties to a civil action may appeal from a final
judgment. <i>Devlin v. Scardelletti</i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CDRM?jcsearch=536%20U.S.%201&amp;summary=yes#jcite">536 U.S. 1</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CDRM?jcsearch=7&amp;summary=yes#jcite">7</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CDRM?jcsearch=122%20supreme%20court%202005&amp;summary=yes#jcite">122 S.Ct. 2005</a>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CDRM?jcsearch=153%20l%20ed%202d%2027&amp;summary=yes#jcite">153 L.Ed.2d 27</a> (2002). The Supreme Court has applied this rule strictly, and
has generally rejected attempts to craft exceptions to the rule.
<i>Microsystems Software, Inc. v. Scandinavia Online AB</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3FKST?jcsearch=226%20f%203d%2035&amp;summary=yes#jcite">226 F.3d 35</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3FKST?jcsearch=226%20f%203d%2035&amp;summary=yes#jcite">39-40</a>
(1st Cir.2000).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Those who intervene in the district court properly become parties and may
appeal a final judgment. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3FKST?jcsearch=226%20F.3d%2035&amp;summary=yes#jcite">Id.at 39</a>. Of course, a nonparty may appeal from the
denial of a motion to intervene. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3FKST?jcsearch=226%20F.3d%2035&amp;summary=yes#jcite">Id.at 40</a>. However, courts are generally
"powerless to extend a right of appeal to a nonparty who abjures
intervention." <i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3FKST?jcsearch=226%20F.3d%2035&amp;summary=yes#jcite">Id</a>.</i>The Supreme Court has recognized only one exception to
this rule: that "nonnamed class members . . . who have objected in a timely
manner to approval of the settlement at the fairness hearing have the power
to bring an appeal without first intervening." <i>Devlin</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CDRM?jcsearch=536%20us%2014&amp;summary=yes#jcite">536 U.S. at 14</a>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CDRM?jcsearch=122%20supreme%20court%202005&amp;summary=yes#jcite">122 S.Ct. 2005</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellant Valerie Samsell clearly has standing to appeal because she was
allowed to intervene in the trial court.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> <i>See Stringfellow v. Concerned</i>
<i>Neighbors in Action</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X5CBDU?jcsearch=480%20us%20370&amp;summary=yes#jcite">480 U.S. 370</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X5CBDU?jcsearch=480%20us%20370&amp;summary=yes#jcite">375-76</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X5CBDU?jcsearch=107%20supreme%20court%201177&amp;summary=yes#jcite">107 S.Ct. 1177</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X5CBDU?jcsearch=94%20l%20ed%202d%20389&amp;summary=yes#jcite">94 L.Ed.2d 389</a>
(1987).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The status of appellants Audrey Rohn and Barbara Sensing is less clear.
Neither Rohn nor Sensing were named parties in the district court
proceedings and neither moved to intervene. Nor did either object to the
final settlement agreement. <i>See Devlin</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CDRM?jcsearch=536%20us%2014&amp;summary=yes#jcite">536 U.S. at 14</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CDRM?jcsearch=122%20supreme%20court%202005&amp;summary=yes#jcite">122 S.Ct. 2005</a>.
Both, however, appear to have objected to the court's cy pres distribution
of unclaimed monies without first distributing additional funds to class
claimants. Dennis Rohn, Audrey Rohn's deceased husband, appears to have
advocated from the outset of the cy pres selection process that the court
give any extra unclaimed funds to consumers who made claims. Barbara Sensing
appears) to have joined Samsell and Rohn in echoing that argument later on,
when the court requested public comment on the proposal submitted by DF/HCC.
The question then becomes whether
<span CLASS="page_no" data-cite="677 f 3d 30" data-cite-type="PrimaryFederalReporter" data-cite-pageno="30" data-primary-citation="677 F.3d 21">[*30]</span> 
<i>Devlin</i>, which created an exception for unnamed class members who have
objected to settlement agreements, extends to this situation in which
unnamed class members have objected to a cy pres distribution. For present
purposes, we need not decide this question because Rohn's and Sensing's
interests are represented on appeal by Samsell, who clearly has standing to
appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Challenge to the Cy Pres Distribution</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  When class <span CLASS="page_no" data-cite="2012 bl 100972 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> actions are resolved by settlement, unclaimed money may remain
in the settlement fund after initial distributions to class members because
some class members cannot be located, some decline to file a claim, or some
have died. Settlement agreements often dispose of these unclaimed monies by
providing for "cy pres" distributions. Cy pres is an equitable doctrine that
has been imported into the very different class-action context from the
field of trusts and estates law:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      In trusts and estates law, cy pres, taken from the Norman French
    expression <i>cy pres comme possible</i>("as near as possible"), "save[s]
    testamentary gifts that otherwise would fail" because their intended
    use is no longer possible. Courts permit the gift to be used for
    another purpose as close as possible to the gift's intended purpose
    In class actions, courts have approved creating cy pres funds, to be
    used for a charitable purpose related to the class plaintiffs'
    injury, when it is difficult for all class members to receive
    individual shares of the recovery and, as a result, some or all of
    the recovery remains.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>In re Pharm. Indus. Average Wholesale Price Litig.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20f%203d%2024&amp;summary=yes#jcite">588 F.3d 24</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20f%203d%2024&amp;summary=yes#jcite">33</a> (1st
Cir.2009) (citations omitted) (quoting <i>In re: Airline Ticket Comm'n</i>
<i>Antitrust Litig.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XE7J6A?jcsearch=307%20f%203d%20679&amp;summary=yes#jcite">307 F.3d 679</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XE7J6A?jcsearch=307%20f%203d%20679&amp;summary=yes#jcite">682</a> (8th Cir.2002)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>In re Pharmaceutical Industry Average Wholesale Price Litigation</i>, we
recognized for the first time in this circuit that settlement agreements may
establish cy pres funds for the distribution of residual unclaimed funds.
<i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20F.3d%2024&amp;summary=yes#jcite">Id.at 33-36</a>. There, this court affirmed the approval of a cy pres fund where
it was part of a settlement agreement that was negotiated at arm's length by
the parties; was not court mandated; some class members would not otherwise
receive recovery; more than actual damages were paid out to class members;
the creation of the cy pres fund facilitated the settlement of a hard-fought
complex action; and the cy pres fund was meant to benefit absent and
non-claimant class members. We rejected the argument that claimants are
entitled to receive any unclaimed residual money, in preference to a cy pres
distribution, regardless of whether they have already been compensated for
their losses. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20F.3d%2024&amp;summary=yes#jcite">Id.at 35</a>. We held that the district court did not abuse its
discretion in approving the cy pres part of the settlement because the
settlement agreement met the American Law Institute's benchmark of "100
percent recovery" for all class members before any money would be
distributed through cy pres. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20F.3d%2024&amp;summary=yes#jcite">Id.at 35-36</a> (citing Am. Law Inst., Principles
of the Law of Aggregate Litigation <cite>&sect; 3.07</cite> cmt. b (Apr. 1, 2009) (proposed
final draft)). This case involves an agreement with these same
characteristics. In our earlier case we did not address questions concerning
the distributions from cy pres funds. We do so for the first time here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review a district court's approval of a proposed class action
settlement for abuse of discretion. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20F.3d%2024&amp;summary=yes#jcite">Id.at 32-33</a>. The abuse of discretion
standard is highly deferential and "not appellant-friendly." <i>Texaco P.R.,</i>
<i>Inc. v. Dep't of Consumer Affairs</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X30NIM?jcsearch=60%20f%203d%20867&amp;summary=yes#jcite">60 F.3d 867</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X30NIM?jcsearch=60%20f%203d%20867&amp;summary=yes#jcite">875</a> (1st Cir.1995)
<span CLASS="page_no" data-cite="677 f 3d 31" data-cite-type="PrimaryFederalReporter" data-cite-pageno="31" data-primary-citation="677 F.3d 21">[*31]</span> 
(quoting <i>Lussier v. Runyon</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3NRJD?jcsearch=50%20f%203d%201103&amp;summary=yes#jcite">50 F.3d 1103</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3NRJD?jcsearch=50%20f%203d%201103&amp;summary=yes#jcite">1111</a> (1st Cir.1995)) (internal
quotation marks omitted). Of course, a material error <span CLASS="page_no" data-cite="2012 bl 100972 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> of law is an abuse of
discretion. <i>Spooner v. EEN, Inc.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1FLHI8003?jcsearch=644%20f%203d%2062&amp;summary=yes#jcite">644 F.3d 62</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1FLHI8003?jcsearch=644%20f%203d%2062&amp;summary=yes#jcite">66</a> (1st Cir.2011).
Ordinarily, however, an abuse of discretion will not be found unless "the
record provides strong evidence that the trial judge indulged a serious
lapse in judgment," <i>Texaco P.R.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X30NIM?jcsearch=60%20f%203d%20867&amp;summary=yes#jcite">60 F.3d at 875</a>, such as if the decision
"ignores a material factor deserving significant weight, relies upon an
improper factor, or assesses only the proper mix of factors but makes a
serious mistake in evaluating them," <i>Downey v. Bob's Disc. Furniture</i>
<i>Holdings, Inc.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1ERKBK003?jcsearch=633%20f%203d%201&amp;summary=yes#jcite">633 F.3d 1</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1ERKBK003?jcsearch=633%20f%203d%201&amp;summary=yes#jcite">5</a> (1st Cir.2011) (quoting <i>Gomez v. Rivera</i>
<i>Rodriguez</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6BD4N?jcsearch=344%20f%203d%20103&amp;summary=yes#jcite">344 F.3d 103</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6BD4N?jcsearch=344%20f%203d%20103&amp;summary=yes#jcite">112</a> (1st Cir.2003)) (internal quotation mark
omitted). We apply the same abuse of discretion standard to questions
regarding a court's approval of distribution from a cy pres fund as part of
a settlement agreement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Samsell plaintiffs frame some of their challenges as attacks on the
underlying consent decree, but they gave up that challenge to the agreement
when they executed the implementation agreement. They have waived any right
to object to the agreement on appeal; indeed they received consideration for
that waiver. After extended negotiations resulting in a 67% increase in
their full damages awards, the Samsell plaintiffs entered into the
implementation agreement in which they agreed to be bound by all terms and
provisions of the settlement agreement and agreed not to appeal from a final
judgment. They also agreed to accept the roughly 167% of their damages as
"fair and reasonable" compensation.<a HREF="#fn400" name="fnref_fn400">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The settlement agreement, which appellants are not free to attack,
explicitly anticipated that there could be unclaimed funds after the
distribution to claimants, and expressly granted the district court broad
discretion to make awards from the cy pres fund.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> The agreement
anticipated that a distribution might be made to appropriate charitable
institutions. It granted TAP tax deduction rights if "all or part of any
unclaimed funds is distributed to one or more charitable organizations."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We turn to the issue of whether the district court abased its discretion,
under the evolving law of cy pres distributions in class action settlement
agreements, in either the process utilized or in the decision to make a cy
pres award of the unclaimed consumer settlement proceeds to DF/HCC.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, the district court considered a supplemental consumer claims process
designed to reach more consumers using previously unavailable patient data
from the Centers for Medicare and Medicaid Services. The district court was
concerned, however, that only 11,000 individuals out of the estimated tens
or hundreds of thousands of class consumers filed claims despite extensive
notice procedures. The
<span CLASS="page_no" data-cite="677 f 3d 32" data-cite-type="PrimaryFederalReporter" data-cite-pageno="32" data-primary-citation="677 F.3d 21">[*32]</span> 
district court appropriately decided that a supplemental consumer claims
process would be prohibitively expensive, time-consuming, and, given the
high mortality rate among members of the class, would likely recruit few new
claimants.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Samsell plaintiffs clarified at oral argument that they are no longer
appealing the district court's choice to arrange a cy pres distribution
rather than to recruit <span CLASS="page_no" data-cite="2012 bl 100972 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> more claims by absent class members. In any event,
there was no abuse of discretion in the district court's choice to forego a
direct notice mailing given that the administrative burden of doing so
appeared to outweigh the small potential for increased claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Instead, the Samsell plaintiffs make several categories of arguments,
which are essentially these:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. That they were entitled to greater distributions in preference to
distributions for the benefit of absent class members because they have not
received treble damages.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  2. That the process used was flawed, including on the grounds that the
judge should have recused himself.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  3. That no award can be made to DF/HCC because:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      a) its doctors are precluded from being recipients of awards by
    the terms of the agreement; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      b) the principles of cy pres are violated in that this is not a
    "next best" award to absent national class members because DF/HCC is
    located in Massachusetts and the research will be primarily focused
    on prostate cancer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Many of these assertions are factually untrue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We turn to the law on distribution of cy pres funds. To the extent the
American Law Institute's Principles of the Law of Aggregate Litigation ("ALI
Principles") provides guidance, it does not support a claim of abuse of
discretion. The ALI Principles set forth proposed rules for the use of a cy
pres distribution in class action settlements. <i>See Am.</i>Law Inst., Principles
of the Law of Aggregate Litigation &sect; 3.07 (2010) [hereinafter "ALI
Principles"]. The ALI Principles express a policy preference<a HREF="#fn600" name="fnref_fn600">[fn6]</a> that
unclaimed funds be redistributed to ensure class members recover their full
losses. This policy preference was motivated by a concern that "few
settlements award 100 percent of a class member's losses, and thus it is
unlikely in most cases that further distributions to class members would
result in more than 100 percent recovery." <i>In re Pharm. Indus.</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20f%203d%2024&amp;summary=yes#jcite">588 F.3d at 24</a> (quoting Am. Law Inst., Principles of the Law of Aggregate
Litigation &sect; 3.07 cmt. b (Apr. 1, 2009) (proposed final draft)). Where class
members have been fully compensated for their losses, this presumption does
not apply.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The ALI Principles also reject the presumption, suggested by a concurring
opinion in <i>Klier v. Elf Atochem North America, Inc.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GFFPM003?jcsearch=658%20f%203d%20468&amp;summary=yes#jcite">658 F.3d 468</a> (5th
Cir.2011), that any residual funds must be returned to the defendant. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GFFPM003?jcsearch=658%20F.3d%20468&amp;summary=yes#jcite">Id.at
482</a> (Jones, J., concurring). The ALI Principles explain that returning
unclaimed funds to the defendant
<span CLASS="page_no" data-cite="677 f 3d 33" data-cite-type="PrimaryFederalReporter" data-cite-pageno="33" data-primary-citation="677 F.3d 21">[*33]</span> 
"would undermine the deterrence function of class actions and the underlying
substantive-law basis of the recovery by rewarding the alleged wrongdoer
simply because distribution to the class would not be viable." ALI
Principles, <cite>&sect; 3.07</cite> cmt. b. Courts have generally agreed with the ALI
Principles. <i>See</i>3 Newberg on Class Actions <cite>&sect; 10:17</cite> (4th ed. 2011). The ALI
Principles also reject escheat to the state as a more preferable option.
<i>See</i>ALI Principles, <cite>&sect; 3.07</cite> cmt. b.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Instead, ALI Principles <cite>&sect; 3.07(c)</cite> sets up an order of preference: when
feasible, the recipients should be those "whose interests reasonably
approximate those being pursued by the class." <i>Id.</i>If no recipients "whose
interests reasonably approximate <span CLASS="page_no" data-cite="2012 bl 100972 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> those being pursued by the class can be
identified after thorough investigation and analysis, a court may approve a
recipient that does not reasonably approximate the interests being pursued
by the class." <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Both case law and the ALI Principles support our adoption of the
"reasonable approximation" test. As to whether distributions reasonably
approximate the interests of the class members, we consider a number of
factors, which are not exclusive. These include the purposes of the
underlying statutes claimed to have been violated, the nature of the injury
to the class members, the characteristics and interests of the class
members, the geographical scope of the class, the reasons why the settlement
funds have gone unclaimed, and the closeness of the fit between the class
and the cy pres recipient.<a HREF="#fn700" name="fnref_fn700">[fn7]</a> Failure to meet the reasonable approximation
test can lead to reversal.<a HREF="#fn800" name="fnref_fn800">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For example, in <i>In re Airline Ticket Commission Antitrust Litigation</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X51948?jcsearch=268%20f%203d%20619&amp;summary=yes#jcite">268 F.3d 619</a> (8th Cir.2001), a national anti-trust class action against
airlines concerning caps on ticket commissions earned by travel agencies,
the Eighth Circuit held that a cy pres distribution of unclaimed funds to
Minnesota law schools and charities was invalid. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X51948?jcsearch=268%20F.3d%20619&amp;summary=yes#jcite">Id.at 625-26</a>. On remand,
the district court ordered the funds distributed to the National Association
for Public Interest Law, "to support attorneys providing legal services to
low income clients by paying the interest on grant recipients' outstanding
student loans." <i>In re: Airline Ticket Comm'n</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XE7J6A?jcsearch=307%20f%203d%20679&amp;summary=yes#jcite">307 F.3d at 682</a>. The Eighth
Circuit reversed again, explaining that the "next best" recipients were not
public interest organizations, but rather the travel agencies in Puerto Rico
and the U.S. Virgin Islands who suffered from the same allegedly unlawful
caps. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XE7J6A?jcsearch=307%20F.3d%20682&amp;summary=yes#jcite">Id.at 683-84</a>. The court remanded the case, ordering that the cy pres
fund be distributed on a proportional basis to those travel agencies. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XE7J6A?jcsearch=307%20F.3d%20682&amp;summary=yes#jcite">Id.at
684</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span CLASS="page_no" data-cite="677 f 3d 34" data-cite-type="PrimaryFederalReporter" data-cite-pageno="34" data-primary-citation="677 F.3d 21">[*34]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Other courts have similarly applied the reasonable approximation test.
<i>See, e.g., Nachshin v. AOL, LLC</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GPA2M003?jcsearch=663%20f%203d%201034&amp;summary=yes#jcite">663 F.3d 1034</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GPA2M003?jcsearch=663%20f%203d%201034&amp;summary=yes#jcite">1040</a> (9th Cir.2011)
(rejecting, in a nation-wide privacy class action, a cy pres distribution to
local Los Angeles charities because it did not "account for the broad
geographic distribution of the class," did not "have anything to do with the
objectives of the underlying statutes," and would not clearly "benefit the
plaintiff class"); <i>Six Mexican Workers v. Ariz. Citrus Growers</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X31DBM?jcsearch=904%20f%202d%201301&amp;summary=yes#jcite">904 F.2d 1301</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X31DBM?jcsearch=904%20f%202d%201301&amp;summary=yes#jcite">1311-12</a> (9th Cir.1990) (invalidating a cy pres distribution
to the Inter-American Fund for "indirect distribution in Mexico," <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X31DBM?jcsearch=904%20F.2d%201301&amp;summary=yes#jcite">id.at
1304</a>, in a class action brought by undocumented Mexican workers regarding
violations of the Farm Labor Contractor Registration Act, because the
distribution was "inadequate to serve the goals of the statute and protect
the interests of the silent class members," <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X31DBM?jcsearch=904%20F.2d%201301&amp;summary=yes#jcite">id.at 1312</a>); <i>Houck v. Folding</i>
<i>Carton Admin. Comm.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3A6BT?jcsearch=881%20f%202d%20494&amp;summary=yes#jcite">881 F.2d 494</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3A6BT?jcsearch=881%20f%202d%20494&amp;summary=yes#jcite">502</a> (7th Cir.1989) (invalidating
settlement agreement, in a national antitrust class action, that made a cy
pres distribution to local law schools, and directing the district court to
"consider to some degree a broader nationwide use of its <i>cy</i>
<i>pres</i>discretion"); <i>In re Folding Carton Antitrust Litig.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XABOIK?jcsearch=744%20f%202d%201252&amp;summary=yes#jcite">744 F.2d 1252</a>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XABOIK?jcsearch=744%20f%202d%201252&amp;summary=yes#jcite">1253-54</a> (7th Cir.1984) (invalidating, <span CLASS="page_no" data-cite="2012 bl 100972 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[**12]</span> in a national antitrust class action,
a cy pres distribution that would establish a private antitrust research
foundation on the basis that "[t]here has already been voluminous research"
on the subject). As these cases make clear, the mere fact that a recipient
is a charitable or public interest organization does not itself justify its
receipt of a cy pres award.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Against these criteria we turn to the Samsell plaintiffs' arguments. They
first argue that the residual funds should have been used first to pay the
claimants their "full out-of-pocket expenses." That is not the measure of
their damages. Only a portion of the sum charged for Lupron was an
overcharge. The Samsell plaintiffs have already received their full damages,
and more. Their damages are not the full price they paid for Lupron; rather,
their damages are the money they paid above the market value of the drug as
a result of the inflated price. The district court found that 30% of the
price the class paid for Lupron was a reasonable estimate of the class's
full damages. The implementation agreement paid the class 50% of the price
they paid for Lupron, which amounts to 167% of their damages.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Samsell plaintiffs argue that even though they have received their
full damages, the district court abused its discretion by choosing to make a
cy pres distribution instead of using the residual funds to award treble
damages to the claimants.<a HREF="#fn900" name="fnref_fn900">[fn9]</a> We disagree. The 11,000 claimants have
already received an enhanced payment beyond single damages. Because the
consumer fund was established for the benefit of all consumer purchasers of
Lupron, not just the 11,000 who filed claims, the court appropriately
determined that the "next best" relief would be a cy pres distribution which
would benefit the potentially large number of absent class members.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a>
Such
<span CLASS="page_no" data-cite="677 f 3d 35" data-cite-type="PrimaryFederalReporter" data-cite-pageno="35" data-primary-citation="677 F.3d 21">[*35]</span> 
relief may yield tangible benefits for class members in the form of lower
prices for existing drugs, more effective or more cost-efficient versions of
current drugs, or even new cures altogether. Such benefits would accrue both
to the claimant class members and to the living absent class members, most
of whom would enjoy the advantages of less expensive or more effective drugs
that combat the multitude of conditions the class faces, which this research
may produce. Moreover, the parties themselves contemplated such use of any
unclaimed funds: the tax provisions of the settlement agreement clearly
provided for the possibility that unclaimed funds would go to a charity to
benefit silent class members.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>In re Pharmaceutical Industry Average Wholesale Price Litigation</i>, we
voiced a concern about overcompensating claimant class members at the
expense of absent class members. <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20f%203d%2024&amp;summary=yes#jcite">588 F.3d at 34-36</a>. There, we rejected the
argument that claimants are entitled to receive a windfall of any unclaimed
residual money regardless of whether they have already been compensated for
their losses. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1C5LTG003?jcsearch=588%20F.3d%2024&amp;summary=yes#jcite">Id.at 35</a>. It is well accepted that protesting class members
are not entitled to windfalls in preference to cy pres distributions. The
Fifth Circuit, for example, <span CLASS="page_no" data-cite="2012 bl 100972 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[**13]</span> has recently stated that "[w]here it is still
logistically feasible and economically viable to make additional pro rata
distributions to class members, the district court should do so, except
where an additional distribution would provide a windfall to class members
with liquidated-damages claims that were 100 percent satisfied by the
initial distribution." <i>Klier</i>, (<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1ALSGM003?jcsearch=558%20f%203d%20461&amp;summary=yes#jcite">558 F.3d at 475</a> (footnote omitted).<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Commentators have agreed that distributing residual funds to claimants who
have already recovered their losses "necessarily results in an undeserved
windfall for those plaintiffs, who have already been compensated for the
harm they have suffered." Martin H. Redish, Peter Julian, &amp; Samantha Zyontz,
<i>Cy Pres Relief and the Pathologies of the Modern Class Action: A Normative</i>
<i>and Empirical Analysis</i>, 62 Fla. L. Rev. 617, 639 (2010); <i>see also</i>2
McLaughlin on Class Actions &sect; 8:15 (8th ed. 2011); Susan Beth Farmer, <i>More</i>
<i>Lessons From The Laboratories: Cy Pres Distributions in Parens Patriae</i>
<i>Antitrust Actions Brought By State Attorneys General</i>, 68 Fordham L. Rev.
361, 393 (1999).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We agree that allowance of such wind-falls "could create a perverse
incentive among victims to bring suits where large numbers of absent class
members were unlikely to make claims. It might also create an incentive for
the represented class members to keep information from the absent class
members." Redish at 632; <i>see also Mirfasihi v. Fleet Mortg. Corp.</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CR6R?jcsearch=356%20f%203d%20781&amp;summary=yes#jcite">356 F.3d 781</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CR6R?jcsearch=356%20f%203d%20781&amp;summary=yes#jcite">785</a> (7th Cir.2004); <i>Van Gemert v. Boeing Co.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3OHB0?jcsearch=553%20f%202d%20812&amp;summary=yes#jcite">553 F.2d 812</a>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3OHB0?jcsearch=553%20f%202d%20812&amp;summary=yes#jcite">816</a> (2d Cir.1977) (explaining that such windfalls may "encourage the
bringing of class actions likely to result in large uncollected damage
pools").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span CLASS="page_no" data-cite="677 f 3d 36" data-cite-type="PrimaryFederalReporter" data-cite-pageno="36" data-primary-citation="677 F.3d 21">[*36]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Samsell plaintiffs argue next that in any event DF/HCC is not a proper
recipient for several reasons. The initial argument is that DF/HCC "profited
from the fraudulent scheme and conspiracy alleged in this case" through its
for-profit members. This claim has no basis in the record. DF/HCC is a
not-for-profit corporation organized under Massachusetts law; it is not a
defendant and the conspiracy claims under RICO against doctors were
dismissed early on. Nor do the Samsell plaintiffs point to any DF/HCC
employee or affiliate who participated in the fraudulent Lupron scheme.
Further, during the cy pres selection process, Samsell herself recommended
that half of the cy pres funds go to DF/HCC.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Samsell plaintiffs lodge several attacks against the cy pres selection
process itself. First, the Samsell plaintiffs argue that the "next best"
requirement is not met because the cy pres recipient, DF/HCC, is in Boston
while the injuries are to a national class. This objection fails. It is not
the location of the recipient which is key; it is whether the projects
funded will provide "next best" relief to the class. DF/HCC is required to
do work which will have benefits well beyond Boston. The DF/HCC proposal
uses a venture capital model to invest in high-impact, high-risk research
projects across the globe, with the expectation that promising results will
attract grants from more traditional funding sources. DF/HCC says it intends
to be a catalyst for large-scale research <span CLASS="page_no" data-cite="2012 bl 100972 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[**14]</span> collaboration by providing
incentives to teams of researchers to join forces at the national and
international levels. Moreover, the grants will be awarded by an Oversight
Board composed of nationwide leaders in prostate cancer research.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Additionally, the claim that only prostate cancer research is being funded
is false. The DF/HCC proposal is specific that "[t]he central and
overarching goal of [the DF/HCC] program is to directly impact the treatment
of prostate cancer and other Lupron-treatable diseases and conditions"
including "endometriosis, uterine fibroids, and/or central precocious
puberty." Indeed, Samsell recommended to the district court that half of the
cy pres funds be distributed to DF/HCC precisely because it would "support[]
research in the treatment of infertility, endometriosis, ovarian and breast
cancer, and precocious puberty," unlike the alternative Loughlin proposal
which focused only on prostate cancer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Samsell plaintiffs also argue that the district court judge erred by
failing to recuse himself from participation in the cy pres distribution on
account of his service as an uncompensated trustee on the board of the
Vincent Memorial Hospital, which is affiliated with the Massachusetts
General Hospital (MGH). MGH, in turn, is affiliated with both Brigham &amp;
Women's Hospital and Harvard Medical School. MGH, Brigham &amp; Women's, and
Harvard Medical School are all member institutions of DF/HCC.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This recusal claim is without merit. Recusal is only required by a state
of mind "so resistant to fair and dispassionate inquiry as to cause a party,
the public, or a reviewing court to have reasonable grounds to question the
neutral and objective character of a judge's rulings or findings." <i>In re</i>
<i>United States</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X484II?jcsearch=158%20f%203d%2026&amp;summary=yes#jcite">158 F.3d 26</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X484II?jcsearch=158%20f%203d%2026&amp;summary=yes#jcite">34</a> (1st Cir.1998). That test is not met here.
More than that, no question is raised here that the selection of the
recipients
<span CLASS="page_no" data-cite="677 f 3d 37" data-cite-type="PrimaryFederalReporter" data-cite-pageno="37" data-primary-citation="677 F.3d 21">[*37]</span> 
was made on any basis other than the merits. <i>See</i>ALI Principles &sect; 3.07.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This recusal claim has also been waived by being raised only on appeal,
which is another indication of its invalidity. Litigants must raise a claim
for disqualification of a district court judge after learning of the grounds
for disqualification, and certainly may not wait and see how the court rules
before acting. <i>Giannetta v. Boucher</i>, No. <cite>92-1488</cite>, <cite>1992 WL 379416</cite>, at *6 (1st
Cir. Dec. 22, 1992) (per curiam) (holding that the appellant waived his
claim of recusal under <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XEIMFQ003?jcsearch=28%20U.S.C.%20%20455(a)&amp;summary=yes#jcite">28 U.S.C. &sect; 455</a>(a) because he failed to raise it in
the district court); <i>In re Abijoe Realty Corp.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3PP9B?jcsearch=943%20f%202d%20121&amp;summary=yes#jcite">943 F.2d 121</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3PP9B?jcsearch=943%20f%202d%20121&amp;summary=yes#jcite">126</a> (1st
Cir.1991) (holding that a party knowing of a ground for requesting
disqualification may not wait to raise the issue until after the judge
issues a ruling that the party dislikes).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Samsell was aware of the judge's service on the board of Vincent; was
aware of the indirect affiliation of Vincent through MGH to DF/HCC; was
aware DF/HCC was a potential recipient; and yet never raised a word of
concern. The district court judge disclosed his affiliation with Vincent
Memorial Hospital at the January 13, 2009 hearing to discuss cy pres award
proposals.<a HREF="#fn1300" name="fnref_fn1300">[fn13]</a> The Samsell plaintiffs were present at the hearing and <span CLASS="page_no" data-cite="2012 bl 100972 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[**15]</span> did
not object upon hearing the disclosure to the judge's continued
participation in the case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There is a double waiver. In 2010, when the judge submitted the final
candidate proposals for public comment, Samsell expressly acknowledged the
judge's participation on the Vincent board, and yet nonetheless recommended
that half of the funds be distributed to DF/HCC. It is only now, for the
first time on appeal, that the Samsell plaintiffs have raised an objection
to the judge's participation in the cy pres selection process.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In a related attack, the Samsell plaintiffs argue that the district court
improperly appointed Dr. Jonathan L. Tilly, a Harvard Medical School
professor, as the court's representative to a committee over-seeing DF/HCC's
use of the cy pres funds. As the district court disclosed in its August 6,
2010 order, Dr. Tilly "has served as a special law clerk to the court," and
is Chief of the Division of Research at the Vincent Center for Reproductive
Biology at MGH. Dr. Tilly is also Chair of the Trustee Committee at the
Vincent Memorial Hospital. We reject this argument for the same reasons
articulated above.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Samsell plaintiffs also argue that the cy pres selection process was
tainted because class counsel simultaneously represented one of the
proposed, but not successful, cy pres recipients, Community Catalyst/PAL.
This is a nonissue since class counsel's proposed cy pres recipient was not
chosen by the district court. Nor was DF/HCC on the list of candidates
selected by class counsel (in fact, class counsel objected to the court's
consideration of DF/HCC).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There was no abuse of discretion in the process used or as to selection of
the recipient.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span CLASS="page_no" data-cite="677 f 3d 38" data-cite-type="PrimaryFederalReporter" data-cite-pageno="38" data-primary-citation="677 F.3d 21">[*38]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although we find no abuse of discretion in this case, and indeed the
process followed was admirable, we express our concerns that district courts
are given discretion by parties to decide on the distribution of cy pres
funds. Our concerns are also stated in the ALI Principles, which stress in <cite>&sect;
3.07(c)</cite> that "the court, when feasible, should <i>require the parties to</i>
<i>identify a recipient</i>whose interests reasonably approximate those being
pursued by the class." (emphasis added). In the commentary, the ALI
Principles also note that the court should give weight to the parties'
choice of recipient as demonstrated by the settlement agreement. ALI
Principles <cite>&sect; 3.07</cite> cmt. b.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is true that the court attempted to compensate for the parties' failure
to designate recipients in the agreement by taking proposals from the
parties and fully involving them in the selection process. But the choice
would have been better made by the parties initially and then tested by the
court, against the principles we have identified.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is one thing for the district court to exercise its traditional
judicial function to approve class action settlement agreements.
<i>See</i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X144L1U003?jcsearch=Fed.R.Civ.P.%2023(e)&amp;summary=yes#jcite">Fed.R.Civ.P. 23(e)</a>. It is quite another for the parties to abandon the
task of agreement over the assignment of residual funds and just hand that
task to the court. The parties expressly contemplated that significant sums
might remain here, and indeed $11.<span CLASS="page_no" data-cite="2012 bl 100972 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[**16]</span> 4 million out of $40 million remained. The
amounts involved also raise concerns. We recognize, as class counsel
candidly articulated, that there are imperfections in all methods of
handling the issue of disposition of residual funds. But the adversary
process is better suited to the parties making the decisions and leaving
less to the discretion of the judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Distribution of funds at the discretion of the court is not a traditional
Article III function, as many courts have recognized:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Federal judges are not generally equipped to be charitable
    foundations: we are not accountable to boards or members for funding
    decisions we make; we are not accustomed to deciding whether certain
    nonprofit entities are more "deserving" of limited funds than
    others; and we do not have the institutional resources and
    competencies to monitor that "grantees" abide by the conditions we
    or the settlement agreements set.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>In re Compact Disc Minimum Advertised Price Antitrust Litig.</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X19A502003?jcsearch=236%20federal%20rules%20decisions%2048&amp;summary=yes#jcite">236 F.R.D. 48</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X19A502003?jcsearch=236%20federal%20rules%20decisions%2048&amp;summary=yes#jcite">53</a> (D.Me.2006); <i>see also</i>Redish at 642.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, having judges decide how to distribute cy pres awards both taxes
judicial resources and risks creating the appearance of judicial
impropriety. A growing number of scholars and courts have observed that "the
specter of judges and outside entities dealing in the distribution and
solicitation of settlement money may create the appearance of impropriety."
<i>Nachshin</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GPA2M003?jcsearch=663%20f%203d%201034&amp;summary=yes#jcite">663 F.3d at 1039</a>; <i>see also SEC v. Bear, Stearns &amp; Co.</i>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3M2911?jcsearch=626%20f%20supp%202d%20402&amp;summary=yes#jcite">626 F.Supp.2d 402</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3M2911?jcsearch=626%20f%20supp%202d%20402&amp;summary=yes#jcite">415</a> (S.D.N.Y.2009). These concerns have been noted in the
media. <i>See</i>George Krueger &amp; Judd Serotta, Op-Ed., <i>Our Class-Action System is</i>
<i>Unconstitutional</i>, Wall St. J., Aug. 6, 2008, at A13; Editorial, <i>When Judges</i>
<i>Get Generous</i>, Wash. Post, Dec. 17, 2007, at A20; Adam Liptak, <i>Doling out</i>
<i>Other People's Money</i>, N.Y. Times, Nov. 26, 2007, at A14.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With that cautionary note, we affirm the cy pres distribution, with one
adjustment to the August 6, 2010 order. We add an explicit requirement that
the district court must receive an annual audit at the expense of DF/HCC, in
addition to the annual and semi-annual accountings to be submitted by DF/HCC
to the court. This will
<span CLASS="page_no" data-cite="677 f 3d 39" data-cite-type="PrimaryFederalReporter" data-cite-pageno="39" data-primary-citation="677 F.3d 21">[*39]</span> 
ensure that the cy pres fund is distributed in a way that is both
financially sound and comports with the interests of the class and that the
auditing function will not fall on the district court. We believe that was
intended by the court and is implicit in its orders. The district court's
November 16, 2010 order, in which it references a "required accounting of
accrued expenditures," suggests it intended to include such an audit
requirement in the August 6, 2010 order.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  So ordered.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> TAP is a wholly owned joint venture of defendants Abbott Laboratories
and Takeda Pharmaceutical Company, Ltd.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> This issue does not implicate the jurisdiction of the courts under
Article III of the Constitution. The Samsell plaintiffs clearly have an
interest in the residual funds that creates a "case or controversy"
sufficient to satisfy the constitutional requirements of injury, causation,
and redressability. <i>See Lujan v. Defenders of Wildlife</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X5CC5D?jcsearch=504%20us%20555&amp;summary=yes#jcite">504 U.S. 555</a>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X5CC5D?jcsearch=112%20supreme%20court%202130&amp;summary=yes#jcite">112 S.Ct. 2130</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X5CC5D?jcsearch=119%20l%20ed%202d%20351&amp;summary=yes#jcite">119 L.Ed.2d 351</a> (1992). Rather, the question is whether the
Samsell plaintiffs should be considered "parties" for the purposes of
appealing the cy pres distribution.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Appellees argue that Valerie Samsell's intervener status has expired.
Samsell was granted intervenor status in 2004 "for the purpose of
participating in the process established by the court for the: evaluation of
the proposed settlement." <i>In re: Lupron Mktg. &amp; Sales Practices Litig.</i>, No.
<cite>01-CV-10861</cite> (D.Mass. Nov. 17, 2004). However, the court continued to treat
Samsell as an intervenor well after the settlement was approved, conferring
her continued intervenor status. <i>See Micro-systems Software, Inc. v.</i>
<i>Scandinavia Online AB</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3FKST?jcsearch=226%20f%203d%2035&amp;summary=yes#jcite">226 F.3d 35</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X3FKST?jcsearch=226%20f%203d%2035&amp;summary=yes#jcite">39</a> (1st Cir.2000); <i>accord In re E. Sugar</i>
<i>Antitrust Litig.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XABLJP?jcsearch=697%20f%202d%20524&amp;summary=yes#jcite">697 F.2d 524</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/XABLJP?jcsearch=697%20f%202d%20524&amp;summary=yes#jcite">527-28</a> (3d Cir.1982). The district court
referred to Samsell as an intervenor during the cy pres selection process,
and most recently, did so again in its August 6, 2010 order.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Those who sought treble damages were given an opportunity to opt out
of the settlement. Many plaintiffs did opt out and filed their own
individual claims in state court. <i>See, e.g., Walker v. TAP Pharm. Prods.,</i>
<i>Inc.</i>, No. <cite>CPML-682-01</cite> (N.J.Super.Ct.); <i>Stetser v. TAP Pharm. Prods., Inc.</i>,
No. <cite>01-CVS-5268</cite> (N.C.Super.Ct.).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> This is not a situation in which the primary purpose of the cy pres
fund is to assure a settlement fund large enough to guarantee substantial
attorney's fees or to make the bringing of the class action worthwhile, a
danger pointed out by commentators. <i>See</i>Martin H. Redish, Peter Julian, &amp;
Samantha Zyontz, <i>Cy Pres Relief and the Pathologies of the Modern Class</i>
<i>Action: A Normative and Empirical Analysis</i>, 62 Fla. L. Rev. 617 (2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> The ALI Principles state: "If the settlement involves individual
distributions to class members and funds remain after distributions (because
some class members could not be identified or chose not to participate), the
settlement should presumptively provide for further distributions to
participating class members unless the amounts involved are too small to
make individual distributions economically viable or other specific reasons
exist that would make such further distributions impossible or unfair." Am.
Law Inst., Principles of the Law of Aggregate Litigation &sect; 3.07(b) (2010)
[hereinafter "ALI Principles"].
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> As Judge Posner has pointed out, the cy pres doctrine under the trust
law "is based on the idea that the settlor would have preferred a modest
alteration in the terms of the trust to having the corpus revert to his
residuary legatees. So there is an indirect benefit to the settlor."
<i>Mirfasihi v. Fleet Mortg. Corp.</i>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CR6R?jcsearch=356%20f%203d%20781&amp;summary=yes#jcite">356 F.3d 781</a>, <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CR6R?jcsearch=356%20f%203d%20781&amp;summary=yes#jcite">784</a> (7th Cir.2004). He
contrasts this with a different rationale in the class action context:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[T]he reason for appealing to cy pres is to prevent the defendant from
walking away from the litigation scot-free because of the infeasibility of
distributing the proceeds of the settlement . . . to the class members.
There is no indirect benefit to the class from the defendant's giving the
money to someone else. In such a case the `cy pres' remedy [is] . . . badly
misnamed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X6CR6R?jcsearch=356%20F.3d%20781&amp;summary=yes#jcite">Id</a>.</i>That is another reason to require the cy pres fund to provide some
benefit to class members, even if indirect.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> One commentary has suggested that abandonment of "next best" relief
intended to be an alternate means of indirectly compensating victims who
could not feasibly be compensated directly would create issues of
constitutional dimension. <i>See</i>Redish at 641-51.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> At oral argument, the Samsell plaintiffs also argued that because this
is a consumer fraud case, the cy pres funds should go to entities that would
combat consumer fraud. This argument, made for the first time at oral
argument, is waived. In any event, we reject the argument. RICO and the
state consumer fraud statutes at issue in this case were meant to protect
vulnerable consumers like the victims in this case. The cy pres distribution
in this case honors that objective by distributing funds to benefit the
absent class members who have not yet been compensated.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> This is not a "fluid class recovery" case in which the court attempts
to direct residual funds "to those who will be impacted by the defendant in
the future, in an effort to roughly approximate the category of those who
were injured in the past." <i>See</i>Redish at 620.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> In <i>Klier v. Elf Atochem North America, Inc.</i>, the court reversed a
district court order imposing a cy pres fund for residual unspent monies
which had not been provided for in the settlement agreement. <a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GFFPM003?jcsearch=658%20f%203d%20468&amp;summary=yes#jcite">658 F.3d 468</a>,
<a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GFFPM003?jcsearch=658%20f%203d%20468&amp;summary=yes#jcite">480</a> (5th Cir.2011). While the defendant had proposed seven cy pres
beneficiaries, the plaintiff opposed and sought additional distributions to
a subclass or alternatively to a different cy pres recipient. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GFFPM003?jcsearch=658%20F.3d%20468&amp;summary=yes#jcite">Id.at 473</a>. The
court found no support in the settlement documents for the creation of a cy
pres fund, in contrast to our case. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GFFPM003?jcsearch=658%20F.3d%20468&amp;summary=yes#jcite">Id.at 476-78</a>. It ordered the district
court to reallocate the funds among the subclasses of the class that
generated the settlement. <i></i><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1GFFPM003?jcsearch=658%20F.3d%20468&amp;summary=yes#jcite">Id.at 480</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> Dennis Rohn joined Samsell in asking the court to give the other half
of the cy pres funds, or at least some portion, to claimant consumers.
Barbara Sensing was not yet involved in the cy pres selection process.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> The judge stated:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
I am on the board at Vincent Memorial Hospital, which is a board at Mass.
General Hospital. We are part of the Partners system. So the question is
whether that is a conflict of interest. . . . I want everyone to understand
that I am not, obviously, a compensated trustee, but I have been affiliated
through Vincent with Mass. General for almost 12 years; now and would not
want anyone to think that I have favored, if this was the direction I would
choose to go, a Mass. General or, for that matter, a Brigham-affiliated
group because of my own personal involvement at the hospital.
</p></div>
</div>
<!--BBLS DD 1705110339587-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HK07U003/history">Direct History (23)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HK07U003/analysis">Case Analysis (14)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HK07U003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
14
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceutical Manufacturing</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LG91SJ82">10-02494 (1st Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/63be6f0340dbaefae64eb65c545b08e3/document/X1Q6LJ01B2O2">11-01329 (1st Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Class Actions</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/63be6f0340dbaefae64eb65c545b08e3/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "63be6f0340dbaefae64eb65c545b08e3";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY3fba6b&previousPageId=&previousActivityInstanceId=ENTITYad4161&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:44:43-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HK07U003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYad4161&previousPageId=&previousActivityInstanceId=ENTITY70e365&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:44:37-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1HK07U003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HK07U003";
$('#page_loader').show().spin();
JUDGE_IDS=["2090089"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
